Physician profile
Thomas L Ashcom
NPI 1689637027
$8,799.02
in general payments reported to CMS, 2019-2025
38 companies · $832 in 2025
The $832 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,363 · 2020: $575 · 2021: $1,302 · 2022: $1,606 · 2023: $942 · 2024: $1,179 · 2025: $832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,770 · Education: $94.99 · Gift: $88.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,769.65 |
| Education | $94.99 |
| Gift | $88.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,450.75 | 2021-2025 | Micra, Symplicity G3, Aurora Ev-Icd Mri Surescan |
| Siemens Medical Solutions USA, INC. | $911.19 | 2019-2025 | Acuson Origin Diagnostic Ultrasound System |
| Astrazeneca Pharmaceuticals LP | $741.02 | 2019-2024 | Wainua, Farxiga |
| Abbott Laboratories | $736.12 | 2019-2023 | Assurity, Dragonfly Opstar |
| Amgen INC. | $684.72 | 2019-2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $589.67 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $547.82 | 2019-2023 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $318.17 | 2019-2024 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $276.46 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $265.74 | 2021-2025 | Verquvo |
| Pfizer INC. | $257.03 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $241.67 | 2021-2025 | Camzyos, Eliquis |
| Medtronic Vascular, INC. | $239.31 | 2019-2020 | |
| Edwards Lifesciences Corporation | $166.39 | 2022 | |
| Abiomed | $149.29 | 2019-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $144.26 | 2022-2025 | Lifevest |
| Amarin Pharma, INC. | $126.59 | 2019 | |
| Novo Nordisk INC | $123.23 | 2024-2025 | Wegovy, Ozempic |
| Inari Medical, INC. | $119.67 | 2021 | |
| Cvrx, INC. | $114.20 | 2022-2023 | Barostim Neo System |
| Penumbra, INC. | $111.34 | 2022 | |
| Sanofi-Aventis U.S. LLC | $92.11 | 2019-2021 | |
| Gilead Sciences, INC. | $47.49 | 2019 | |
| Boston Scientific Corporation | $40.77 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $35.91 | 2019-2025 | Evkeeza |
| Coala Life INC | $35.13 | 2022 | |
| Astellas Pharma US INC | $34.67 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $30.45 | 2023 | Arcalyst |
| Bardy Diagnostics, INC. | $28.37 | 2020 | |
| Esperion Therapeutics, INC. | $28.08 | 2020-2021 | |
| Getinge USA Sales, LLC | $24.31 | 2021 | |
| Teleflex LLC | $19.50 | 2025 | Guideliner |
| Bayer Healthcare Pharmaceuticals INC. | $18.71 | 2025 | |
| Heartflow, INC. | $17.79 | 2025 | |
| Alnylam Pharmaceuticals INC. | $15.98 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $15.11 | 2023 | Inpefa |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Ashcom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.